Literature DB >> 19651635

The impact of previous or concomitant myocardium revascularization on the outcomes of patients undergoing major non-cardiac surgery.

Hong Zhang1, Dong-xin Wang, Feng Xiao, Jian Li, Zhi-song He, Yuan-lian Wan.   

Abstract

The aim of this study was to analyze the results of major non-cardiac surgery in patients with severe coronary arterial disease who underwent concomitant vs. previous myocardial revascularization (MR) in terms of operative complications and hospital stay. Between June 1999 and October 2008, 37 patients with coronary arterial disease underwent neoplastic resection at our hospital. Fourteen patients with a curable left-main or multiple-vessel disease received surgical MR concomitantly, while 23 patients previously underwent surgical or transluminal MR. Univariate analysis determined the impact of the timing of MR on operative complications and hospital stay. The overall mortality and morbidity rates were 3% and 65%, respectively. Compared with simultaneous MR, neoplastic surgery with previous MR had shorter postoperative hospital stay. Occurrence of postoperative complications was influenced by surgical duration (P=0.014). Postoperative length of hospital stay was affected by the timing of revascularization (P=0.008) and surgical duration (P=0.007). Previous MR can shorten postoperative hospital length of stay for current major non-cardiac surgeries in patients with severe coronary artery disease (CAD). For patients with concomitant severe CAD and clinically rapidly progressive malignant neoplasm, simultaneous neoplastic resection and MR is associated with acceptable operative mortality.

Entities:  

Mesh:

Year:  2009        PMID: 19651635     DOI: 10.1510/icvts.2009.208512

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  1 in total

1.  Concomitant off-pump coronary artery bypass and non-cardiovascular surgery.

Authors:  Hong Chul Oh; Jung Wook Han; Jae-Woong Choi; Yong Han Kim; Ho Young Hwang; Ki-Bong Kim
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.